The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Growth In Market Value Is Anticipated For The Viral Vectors And Plasmid DNA Market Between 2026 And 2030?
The viral vectors and plasmid dna market has seen significant expansion in recent years. Its value is expected to rise from $1.38 billion in 2025 to $1.47 billion in 2026, with a compound annual growth rate (CAGR) of 6.2%. Historically, this growth can be attributed to several factors including the restricted availability of viral vectors, reliance on research-grade plasmid dna, an increase in gene therapy pipelines, heightened biopharmaceutical research and development activities, and the adoption of conventional viral vector platforms.
The viral vectors and plasmid dna market size is forecast to show robust expansion over the next few years. It is expected to grow to $1.89 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.6%. This projected growth stems from factors such as the advancement of clinical-grade and GMP plasmid DNA, the wider application of viral vectors in treating cancer and infectious diseases, increased investment in gene therapy, a growing demand for immunotherapy solutions, and the adoption of innovative vector platforms like AAV and lentiviral vectors. Notable trends anticipated during this period include the increasing uptake of plasmid DNA and viral vectors in gene therapy, the broadening of viral vector platforms for cancer and genetic disorder treatments, a rise in GMP-grade plasmid DNA production for clinical uses, intensified research into novel adeno-associated and lentiviral vectors, and the incorporation of plasmid DNA and viral vectors in immunotherapy and vaccine development.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3245&type=smp
Which Core Factors Are Supporting The Expansion Of The Viral Vectors And Plasmid DNA Market?
The increasing prevalence of tuberculosis cases is anticipated to stimulate the expansion of the viral vector and plasmid DNA market in the future. Tuberculosis (TB) is a contagious and potentially serious bacterial infection that primarily affects the lungs but can also impact other bodily systems. Plasmid DNA vaccines are utilized to deliver microbial antigen-coding genes for tuberculosis. These vaccines can be engineered to express specific antigens from Mycobacterium tuberculosis, the bacterium responsible for the disease, and are administered via intramuscular injection. For instance, in February 2024, GOV.UK, a UK-based government department, reported that tuberculosis (TB) cases in England saw a 10.7% increase in 2023, rising from 4,380 in 2022 to 4,850. Consequently, the rising incidence of tuberculosis cases is propelling the growth of the viral vector and plasmid DNA market.
How Is The Viral Vectors And Plasmid DNA Market Distributed Across Key Segments?
The viral vectors and plasmid dna market covered in this report is segmented –
1) By Product: Plasmid DNA, Viral Vectors
2) By Disease: Infectious Diseases, Genetic Disorders, Cancer, Other Diseases
3) By Application: Gene And Cancer Therapies, Viral Infections, Immunotherapy, Formulation Development, Other Applications
4) By End User: Research Institutes, Biopharmaceutical And Pharmaceutical Companies
Subsegments:
1) By Plasmid DNA: Research-Grade Plasmid DNA, Clinical-Grade Plasmid DNA, GMP (Good Manufacturing Practice) Plasmid DNA
2) By Viral Vectors: Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Vesicular Stomatitis Virus (VSV) Vectors
Which Trends Are Influencing The Expansion Of The Viral Vectors And Plasmid DNA Market?
Leading companies in the viral vectors and plasmid DNA market are intensifying their efforts to introduce innovative products, such as helper plasmids, to gain a competitive advantage. A helper plasmid is a form of plasmid DNA crucial for the production of viral vectors, including adeno-associated viral vectors (AAV), which are frequently used in gene therapy. For instance, in March 2023, Charles River Laboratories International Inc., a US-based pharmaceutical company, launched its off-the-shelf pHelper. This helper plasmid aims to accelerate the entire process from initial discovery to the commercial manufacture of adeno-associated virus (AAV)-based gene therapy programs and to secure necessary supplies. As the newest addition to an extensive range of contract development and manufacturing organization (CDMO) products and services, helper plasmids are engineered to protect viral vector packaging during cell and gene therapy operations and to simplify complex supply chains. Helper plasmids are instrumental in creating adeno-associated viral vectors (AAV), which are commonly utilized in gene therapy.
Who Are The Companies Shaping The Viral Vectors And Plasmid DNA Market Landscape?
Major companies operating in the viral vectors and plasmid dna market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza Group AG, Cobra Biologics and Pharmaceutical Services, Brammer Bio, ??n?k? ??r??r?t??n, Cell and Gene Therapy Catapult, VGXI Inc., MassBiologics, Sanofi, Spark Therapeutics, UniQure NV, Thermo Fisher Scientific, VIROVEK, SIRION Biotech GmbH, ALDEVRON, Oxford BioMedica, PlasmidFactory GmbH & Co. KG, Biovian Oy, BioReliance Corporation, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Vigene Biosciences Inc., Novasep, Genzyme Corporation, Oxford Gene Technology, Richter-Helm, MolMed, Merck KGaA Inc., Catalent Inc., WuXi AppTec, GenScript Biotech Corporation, Eurogentec, Creative Biogene
Access The Complete Viral Vectors And Plasmid DNA Market Report:
https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report
Which Region Stands As The Largest Contributor To The Viral Vectors And Plasmid DNA Market?
North America was the largest region in the viral vectors and plasmid DNA market in 2025. The Middle East is expected to be the fastest-growing region in the global viral vectors & plasmid DNA market analysis. The regions covered in the viral vectors and plasmid dna market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Viral Vectors And Plasmid DNA Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=3245&type=smp
Browse Through More Reports Similar to the Global Viral Vectors And Plasmid DNA Market 2026, By The Business Research Company
Anti Infective Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market
Antivirals Market Report 2026
https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report
Hospital Acquired Infections Testing Kits Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model